海思科(002653.SZ)：多项药物临床试验获批准

Core Viewpoint - The company has received approval for clinical trials of multiple drug candidates from the National Medical Products Administration, indicating progress in its research and development efforts [1] Group 1: Company Developments - The subsidiary Shanghai Hisun Shennuo Pharmaceutical Technology Co., Ltd. has been granted the Clinical Trial Approval Notice for HSK45019 tablets, HSK50042 tablets, injectable HSK55718, and HSK36357 capsules [1] - The approved drug candidates target various indications, including inflammatory bowel disease, respiratory diseases, acute pain, and muscular dystrophy [1]